| Literature DB >> 17973318 |
Shakeel Modak1, Neeta Pandit-Taskar, Brian H Kushner, Kim Kramer, Peter Smith-Jones, Steven Larson, Nai-Kong V Cheung.
Abstract
Radioiodinated metaiodobenzylguanidine [(131)I-MIBG] is commonly used to treat resistant neuroblastoma or metastatic pheochromocytoma [MP] with little non-hematopoietic toxicity. We describe here transient sialoadenitis, a previously unreported complication. Ten patients [9 neuroblastoma and 1 MP] received 12-18 mCi/kg of (131)I-MIBG. Five patients had bilateral parotid swelling, two with associated buccal discomfort within 24 hr of injection which subsided within 48 hr. Grade 3 or 4 serum amylase elevation was documented in 8/8 patients tested [median 1,336; range: 576-8,830 U/L] which normalized [25-125 U/L] within 4-14 [median 5.5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia. (c) 2007 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2008 PMID: 17973318 DOI: 10.1002/pbc.21391
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167